LILRB2 is known to inhibit immune cell activity and modulate the tumor immune microenvironment through its interaction with ligands such as HLA-G, angiopoietin-like protein 2, and semaphorin-4A, thereby promoting tumor cell proliferation and metastasis (Cai et al., 2019). Here, HLA-G is linked to neoplasm.